Antibiotics

Research presented at the 2018 ASM Microbe Meeting has reinforced the value of the just-approved next-generation aminoglycoside antibiotic, plazomicin, in treating multidrug-resistant Enterobacteriaceae.

Because of the global rise in antimicrobial resistance, meropenem-vaborbactam, the first carbapenem/β-lactamase combina­tion medication, is a welcome new antibac­terial.

The new edition is fully electronic and makes key changes related to antimicrobial resistance and HIV.

Catheter-associated urinary tract infections (CAUTIs) account for about 40% of all nosocomial infections in hospitals and nursing homes.

Patient and institutional history, as well as the individual niches of the new antibiotics, need to be considered when selecting a treatment for gram-negative infections.

Several recent studies provide valuable insight surrounding the appropriateness of transitioning from intravenous to oral therapy when treating bacteremic urinary tract infections.

IMI/REL was effective against isolates from the United States and Europe.